WE-Dapa M Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 500 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled on diet and exercise alone. Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, thereby promoting glycosuria and lowering plasma glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. The extended-release formulation allows for once-daily dosing, improving patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. WE-Dapa M Tablet ER should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose. Caution is advised in patients with renal impairment, liver dysfunction, or risk factors for lactic acidosis. Common adverse effects may include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and hypoglycemia when used with other antidiabetic agents. Regular assessment of renal function and electrolyte balance is recommended during therapy. This combination offers a complementary mechanism of action to optimize glycemic control in type 2 diabetes patients.